These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 9806657)

  • 41. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
    Muggia FM; Groshen S; Russell C; Jeffers S; Chen SC; Schlaerth J; Curtin J; Morrow CP
    Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling toxicity and response in carboplatin-based combination chemotherapy.
    Egorin MJ; Reyno LM; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):7-19. PubMed ID: 7992070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
    Vallejos C; Solidoro A; Gómez H; Castellano C; Barriga O; Galdos R; Casanova L; Otero J; Rodriguez W
    Gynecol Oncol; 1997 Nov; 67(2):168-71. PubMed ID: 9367702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
    Fanning J; Bennett TZ; Hilgers RD
    Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin].
    Willemse PH; Blom van Assendelft PH; Fontein DL; Kloppenburg M; Boonstra H; de Vries EG
    Ned Tijdschr Geneeskd; 1991 Aug; 135(35):1588-92. PubMed ID: 1922489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.
    Linasmita V; Wilailak S; Srisupundit S; Tangtrakul S; Bullangpoti S; Israngura N
    J Med Assoc Thai; 1998 Jan; 81(1):10-6. PubMed ID: 9470316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
    Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
    Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.
    Hoskins PJ; Swenerton KD; Pike JA; McMurtrie EM; Lee N
    Gynecol Oncol; 1996 Dec; 63(3):345-51. PubMed ID: 8946870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
    De Lena M; Lorusso V; Romito S
    Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
    Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
    Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
    Sawada M; Ozaki M; Inagaki M; Hongo J; Hirota Y; Takayama K; Arimoto Y; Wada T; Taki I; Yanagita T
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3301-4. PubMed ID: 3120644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The value of platinum dose intensity in first-line therapy on subsequent disease follow-up of epithelial ovarian carcinoma].
    Gruböck K
    Wien Klin Wochenschr; 1994; 106(11):362-6. PubMed ID: 8053205
    [No Abstract]   [Full Text] [Related]  

  • 56. Cyclophosphamide, epirubicin and cisplatin (CEP) in advanced breast cancer: preliminary results.
    Zaniboni A; Marpicati P; Simoncini E; Gorni F; Ferrari V; Raffaglio E; Garattini MP; Marini G
    Anticancer Res; 1987; 7(4B):813-5. PubMed ID: 3479042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
    Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
    Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Recent advances in ovarian cancer chemotherapy from the survival standpoint].
    Hatae M; Onishi Y; Maeda Y; Maeda T; Hirano T; Kamitomo M
    Gan To Kagaku Ryoho; 1995 May; 22(6):718-25. PubMed ID: 7755379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.